Market Intelligence, Polyamine Pathway Biology, and High-Purity Reagents for Cancer & Inflammation Drug Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for SMOX drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SMOX Recombinant Protein (Wild-Type & Catalytic Mutants) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. FAD-binding domain intact. Theoretical MW confirmed. |
View SMOX Products |
| Gene Delivery | SMOX Lentivirus & Promise-ORF Full-length ORF for stable cell line construction and intracellular target validation. |
View SMOX Products |
| Benchmark Ab | Anti-SMOX Validation Antibody (Recombinant rabbit monoclonal) Positive control for Western/IHC/ICC; sequence-verified for biomarker screening. |
View SMOX Products |
| Validator | SMOX siRNA Set For specific knockdown and specificity verification in cell-based assays. |
View SMOX Products |
| Related Target: ODC1 | Ornithine Decarboxylase 1 Rate-limiting enzyme in polyamine synthesis; synergistic targeting with SMOX. |
View ODC1 Products |
| Related Target: PAOX | Polyamine Oxidase Peroxisomal back-conversion enzyme; essential counter-screening target for selectivity profiling. |
View PAOX Products |
| Related Target: SAT1 | Spermidine/Spermine N1-Acetyltransferase 1 Counter-regulatory catabolic enzyme; explore synthetic lethality with SMOX inhibition. |
View SAT1 Products |
| Related Target: AZIN2 | Antizyme Inhibitor 2 Polyamine homeostasis regulatory partner; for advanced mechanism studies. |
View AZIN2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| FAD-dependent enzymatic activity requires properly folded holoenzyme | HEK293 expressed SMOX with theoretical MW match and >95% purity; FAD-binding domain sequence verified |
| Selectivity over related polyamine oxidases and lysyl oxidase family | Homolog panel available (PAOX, LOXL2, LOXL4) for cross-reactivity and counter-screening assays |
| Need for drug-resistant mutant panels to pre-empt clinical escape | Custom mutant SMOX proteins (catalytic domain variants) available for resistance mechanism and selectivity profiling |
| Cross-species cyno/mouse evaluation | Human/Mouse/Cyno ortholog proteins available with sequence-verified identity for translational PK/PD studies |
| Lack of standardized positive controls for cellular target engagement | Lentivirus-based stable overexpression lines and validated siRNA for knockdown/rescue assays |
| Assay specificity confirmation | Validated siRNA and antibody pairs included for orthogonal target engagement verification |
Live SMOX R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SMOX (Spermine oxidase) therapeutics is intensifying as the polyamine metabolism field shifts beyond ODC1 inhibition. SMOX generates hydrogen peroxide during spermine oxidation, driving DNA damage and inflammatory signaling implicated in gastric, colorectal, and prostate cancers. The landscape is transitioning from academic tool compounds (e.g., MDL-72527 analogs) to structure-based clinical candidates. As first-generation ODC inhibitors face compensatory SMOX upregulation, the next wave of R&D focuses on dual-pathway blockade and oxidative stress modulation, including combination therapies with immune checkpoint inhibitors. Key indications include H. pylori-induced gastritis, colorectal neoplasia, and inflammatory bowel disease.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Academic/Biotech consortia | Gastric Cancer, Colorectal Cancer, Prostate Cancer | Enzymatic Activity Assay (Need active, FAD-loaded recombinant SMOX) |
| PROTAC / Degrader | Early-stage discovery programs | Solid Tumors | Intracellular Target Engagement (Need Lentivirus/siRNA for cellular validation; high-purity SMOX for ternary complex) |
| Diagnostics (IHC) | Oncology Biomarker Developers | H. pylori-induced Gastritis, Lung Cancer | Biomarker Validation (Sequence-verified antibodies) |
| Gene Therapy / RNAi | Early-stage Innovators | Inflammatory Bowel Disease (IBD) | Knockdown Verification (Validated siRNA sets) |
| Combination with ODC1 Inhibitors | Translational research groups | Cancer Chemoprevention | Pathway Panel Screening (Need ODC1, SAT1, PAOX ortholog proteins) |
Key Mutations & Biomarker Insights
Known genetic variants in SMOX include dbSNP:rs6084654 (UniProt VAR_059114) and a somatic mutation found in a breast cancer sample (UniProt VAR_036546). These mutations may influence enzymatic activity or substrate specificity and are relevant for designing resistant mutant panels and biomarker assays.